Federal Center for the Development of Biotechnology and Medicine, Moscow State University. N.P. Ogaryov

History

2025: Opening of the centre

January 16, 2025 at Mordovian State University. N.P. Ogaryova began the work of the Federal Center for the Development of Biotechnology and Medicine. The strategic scientific facility was created on behalf of the President of Russia, with the support of the Head of the Republic of Mordovia and the innovative biopharmaceutical company Promomed.

𝓲

Фото: Promomed

The purpose of the center is to localize developments and ensure a full cycle of production of new biotechnological drugs in Russia. Including for the treatment of cancer and autoimmune diseases.

The previously opened centers only supported the development of biosimilars, that is, they provided affordable prices for drugs. This is important and necessary, but this is not a breakthrough yet. The research center was opened precisely for the development stage, the place where drugs will appear, - said Pyotr Beliy, Chairman of the Board of Directors of the PROMOMED Group.

The total amount of funds raised to create the center amounted to 300 million rubles, of which 125.2 million was a special part of the federal program "Priority 2030."

The opening of the Federal Center for the Development of Biotechnology and Medicine is an important event that we went to for a reason. We have the support of our President and serious tasks from him, for which we are responsible. The operation of this project opens up opportunities for import substitution and export of medical services. I hope that this will strengthen the university's position in the Priority 2030 project and achieve success both in the scientific and financial spheres. This is only the beginning of a long journey, - said Artyom Zdunov, Head of the Republic of Mordovia.

As of January 2025, the first part of the center was created and put into operation. It includes laboratories of microbiology, genetically engineered biological products and cellular technologies and is designed to ensure the development of key stages of production and quality control of biotechnological drugs in Russia.

The center's infrastructure will also include an educational block and a university hospital. It will become a platform for mastering the practical skills of medical students, chemists, biotechnologists and pharmacists. A team of students has already been formed.

In 2025, it is planned to accredit the existing laboratories of the center, build a vivarium and continue work on preclinical and clinical research of new medicines. All this is aimed at ensuring a full cycle of production of new drugs in Russia and achieving its drug sovereignty.